RNN Insider Trading Activity and SEC Form 4 Filings
RNN insider trading summary
No open-market insider purchases or sales of Rexahn Pharmaceuticals, Inc. (RNN) have been reported on SEC Form 4 in the past 12 months.
Latest RNN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 31, 2019 | Charles Beever | Insider | Buy | $6K (10,000 @ $0.64) |
| Jan 30, 2019 | Lisa Nolan | Chief Business Officer | Buy | $13K (20,000 @ $0.65) |
| Jan 29, 2019 | Ben Gil Price | Insider | Buy | $9K (15,000 @ $0.61) |
| Jan 29, 2019 | Douglas J Swirsky | President and CEO | Buy | $32K (50,000 @ $0.63) |
| Apr 10, 2017 | Chang Ho Ahn | Insider | Sell | $175K (250,000 @ $0.70) |
| Jan 12, 2015 | Chang Ho Ahn | Director | Sell | $44K (48,444 @ $0.91) |
| Jan 12, 2015 | Tae Heum Jeong | Chief Financial Officer | Sell | $45K (49,800 @ $0.91) |
| Jan 9, 2015 | Chang Ho Ahn | Director | Sell | $170K (186,212 @ $0.92) |
| Jan 9, 2015 | Tae Heum Jeong | Chief Financial Officer | Sell | $173K (188,690 @ $0.92) |
| Jan 8, 2015 | Chang Ho Ahn | Director | Sell | $72K (80,000 @ $0.90) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.